A switch in RND3-RHOA signaling is critical for melanoma cell invasion following mutant-BRAF inhibition

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Klein, R Matthew ^a   Higgins, Paul J ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MUTANT PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; 2 [4 (2 DIMETHYLAMINOETHOXY)PHENYL] 4 (1 HYDROXYIMINO 5 INDANYL) 5 (4 PYRIDINYL) 1H IMIDAZOLE; BRAF PROTEIN, HUMAN; HYBRID PROTEIN; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; PLX 4720; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA PROTEIN, HUMAN; RND3 PROTEIN, HUMAN; SB-590885; SULFONAMIDE;

ARTICLE; CELL INVASION; CELL SHAPE; CELL SUBPOPULATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; MELANOMA CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; AMINO ACID SUBSTITUTION; CANCER INVASION; CELL MOTION; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENE SILENCING; GENETICS; HUMAN; MELANOMA; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

AMINO ACID SUBSTITUTION; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMIDAZOLES; INDOLES; MELANOMA; MUTANT PROTEINS; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS B-RAF; RECOMBINANT FUSION PROTEINS; RHO GTP-BINDING PROTEINS; RHOA GTP-BINDING PROTEIN; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; SULFONAMIDES;

EID: 80052826046     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-114     Document Type: Article

References (25)

1. ACS American Cancer Society. Cancer Facts and Figures 2010. Atlanta: American Cancer Society 2010, ACS.
2. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954. 10.1038/nature00766, 12068308.
3. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 2003, 63:5198-5202.
4. Hoeflich KP, Gray DC, Eby MT, Tien JY, Wong L, Bower J, Gogineni A, Zha J, Cole MJ, Stern HM, et al. Oncogenic BRAF Is Required for Tumor Growth and Maintenance in Melanoma Models. Cancer Res 2006, 66:999-1006. 10.1158/0008-5472.CAN-05-2720, 16424035.
5. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, et al. From the Cover: Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proceedings of the National Academy of Sciences 2008, 105:3041-3046.
6. Lee JT, Li L, Brafford PA, Van Den Eijnden M, Halloran MB, Sproesser K, Haass NK, Smalley KSM, Tsai J, Bollag G, Herlyn M. PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell & Melanoma Research 2010, 23:820-827. 10.1111/j.1755-148X.2010.00763.x, 21922517.
7. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467:596-599. 10.1038/nature09454, 2948082, 20823850.
8. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. Inhibition of Mutated, Activated BRAF in Metastatic Melanoma. N Engl J Med 2010, 363:809-819. 10.1056/NEJMoa1002011, 20818844.
9. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. N Engl J Med
10. Smalley KSM, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006, 5:1136-1144.
11. Meier F, Busch S, Lasithiotakis K, Kulms D, Garbe C, Maczey E, Herlyn M, Schittek B. Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. British Journal of Dermatology 2007, 156:1204-1213. 10.1111/j.1365-2133.2007.07821.x, 17388918.
12. Klein RM, Spofford LS, Abel EV, Ortiz A, Aplin AE. B-RAF Regulation of Rnd3 Participates in Actin Cytoskeletal and Focal Adhesion Organization. Mol Biol Cell 2008, 19:498-508. 2230594, 18045987.
13. Klein RM, Aplin AE. Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensions. Cancer Res 2009, 69:2224-2233. 10.1158/0008-5472.CAN-08-3201, 2657934, 19244113.
14. Chardin P. Function and regulation of Rnd proteins. Nat Rev Mol Cell Biol 2006, 7:54-62. 10.1038/nrm1788, 16493413.
15. Riento K, Guasch RM, Garg R, Jin B, Ridley AJ. RhoE binds to ROCK I and inhibits downstream signaling. Mol Cell Biol 2003, 23:4219-4229. 10.1128/MCB.23.12.4219-4229.2003, 156133, 12773565.
16. Wennerberg K, Forget M-A, Ellerbroek SM, Arthur WT, Burridge K, Settleman J, Der CJ, Hansen SH. Rnd proteins function as RhoA antagonists by activating p190 RhoGAP. Curr Biol 2003, 13:1106-1115. 10.1016/S0960-9822(03)00418-4, 12842009.
17. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, van Belle P, Elder DE, Herlyn M. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003, 63:756-759.
18. Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, Wood E, Fedorenko IV, Sondak VK, Anderson AR, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 2011, 71:2750-2760. 10.1158/0008-5472.CAN-10-2954, 21317224.
19. King AJ, Patrick DR, Batorsky RS, Ho ML, Do HT, Zhang SY, Kumar R, Rusnak DW, Takle AK, Wilson DM, et al. Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic BRAF by the Kinase Inhibitor SB-590885. Cancer Res 2006, 66:11100-11105. 10.1158/0008-5472.CAN-06-2554, 17145850.
20. Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, et al. Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma. Cancer Res 2008, 68:4853-4861. 10.1158/0008-5472.CAN-07-6787, 2692356, 18559533.
21. Paraiso KH, Fedorenko IV, Cantini LP, Munko AC, Hall M, Sondak VK, Messina JL, Flaherty KT, Smalley KSM. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 2010, 102:1724-1730. 10.1038/sj.bjc.6605714, 2883709, 20531415.
22. Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, Kolis S, Zhao S, Lee R, Grippo JF, et al. RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models. Cancer Res 2010, 70:5518-5527. 10.1158/0008-5472.CAN-10-0646, 20551065.
23. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, et al. Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010, 18:683-695. 10.1016/j.ccr.2010.11.023, 21156289.
24. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468:968-972. 10.1038/nature09627, 3058384, 21107320.
25. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973-977. 10.1038/nature09626, 21107323.